The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in PLoS Medicine.

In the paper, Naftali Kaminski, MD, director of the Dorothy P. & Richard P. Simmons Center for Interstitial Lung Disease in the Division of Pulmonary, Allergy and Critical Medicine at the University of Pittsburgh School of Medicine, and his colleagues describe a combination of blood proteins that appear to distinguish IPF patients from normal controls with extraordinary sensitivity and precision.

This article was published in Drug Discovery & Development magazine: Vol. 11, No. 5, May, 2008, pp. 40.